NL8802274A - Zetpillen. - Google Patents

Zetpillen. Download PDF

Info

Publication number: NL8802274A
Authority: NL; Netherlands
Prior art keywords: suppository; calcitonin; suppositories; acid; taurocholic acid
Prior art date: 1987-09-15

Application number

NL8802274A

Other languages

English (en)

Dutch (nl)

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-15

Filing date

1988-09-15

Publication date

1989-04-03

1987-09-15 Priority claimed from GB878721700A external-priority patent/GB8721700D0/en

1988-01-29 Priority claimed from GB888801991A external-priority patent/GB8801991D0/en

1988-03-03 Priority claimed from GB888805068A external-priority patent/GB8805068D0/en

1988-09-15 Application filed by Sandoz Ag filed Critical Sandoz Ag

1989-04-03 Publication of NL8802274A publication Critical patent/NL8802274A/nl

Links

239000000829 suppository Substances 0.000 claims description 53
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 40
108060001064 Calcitonin Proteins 0.000 claims description 27
102000055006 Calcitonin Human genes 0.000 claims description 26
229960004015 calcitonin Drugs 0.000 claims description 25
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 19
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims description 19
239000002511 suppository base Substances 0.000 claims description 17
150000003839 salts Chemical class 0.000 claims description 15
108010068072 salmon calcitonin Proteins 0.000 claims description 13
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 12
238000000034 method Methods 0.000 claims description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
229930195725 Mannitol Natural products 0.000 claims description 7
239000000594 mannitol Substances 0.000 claims description 7
235000010355 mannitol Nutrition 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 5
159000000000 sodium salts Chemical class 0.000 claims description 5
239000000872 buffer Substances 0.000 claims description 4
241000972773 Aulopiformes Species 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000012458 free base Substances 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
235000019515 salmon Nutrition 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 claims description 2
101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 1
239000003021 water soluble solvent Substances 0.000 claims 1
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 14
238000002360 preparation method Methods 0.000 description 13
239000003623 enhancer Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 6
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
229960004106 citric acid Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
150000004683 dihydrates Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
235000019263 trisodium citrate Nutrition 0.000 description 3
229940038773 trisodium citrate Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000005303 weighing Methods 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229910052799 carbon Chemical group 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
238000011555 rabbit model Methods 0.000 description 2
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
102000017631 Calcitonin-like Human genes 0.000 description 1
108050005865 Calcitonin-like Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
240000004658 Medicago sativa Species 0.000 description 1
235000010624 Medicago sativa Nutrition 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000002812 cholic acid derivative Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
239000003074 deoxycholic acid derivative Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000003804 extraction from natural source Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
208000030915 hypercalcemia disease Diseases 0.000 description 1
230000001184 hypocalcaemic effect Effects 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000011368 organic material Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
-1 polyoxyethylene cetyl ether Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000003825 pressing Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000004080 punching Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical group [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Bakery Products And Manufacturing Methods Therefor (AREA)

NL8802274A 1987-09-15 1988-09-15 Zetpillen. NL8802274A (nl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB878721700A GB8721700D0 (en)	1987-09-15	1987-09-15	Organic compounds
GB8721700		1987-09-15
GB8801991		1988-01-29
GB888801991A GB8801991D0 (en)	1988-01-29	1988-01-29	Improvements in/relating to organic compounds
GB888805068A GB8805068D0 (en)	1988-03-03	1988-03-03	Improvements in/relating to organic compounds
GB8805068		1988-03-03

Publications (1)

Publication Number	Publication Date
NL8802274A true NL8802274A (nl)	1989-04-03

Family

ID=27263605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8802274A NL8802274A (nl)	1987-09-15	1988-09-15	Zetpillen.

Country Status (26)

Country	Link
US (1)	US5149537A (no)
JP (1)	JPH01228919A (no)
KR (1)	KR970003052B1 (no)
AT (1)	AT396424B (no)
AU (1)	AU614769B2 (no)
BE (1)	BE1001937A3 (no)
CA (1)	CA1330417C (no)
CH (1)	CH677320A5 (no)
CY (1)	CY1763A (no)
DE (1)	DE3830245A1 (no)
DK (1)	DK509888A (no)
ES (1)	ES2012119A6 (no)
FI (1)	FI87889C (no)
FR (1)	FR2620331B1 (no)
GB (1)	GB2209670B (no)
HK (1)	HK19394A (no)
HU (1)	HU203204B (no)
IL (1)	IL87747A (no)
LU (1)	LU87334A1 (no)
MY (1)	MY103611A (no)
NL (1)	NL8802274A (no)
NO (1)	NO175518C (no)
NZ (1)	NZ226162A (no)
PH (1)	PH24766A (no)
PT (1)	PT88491B (no)
SE (1)	SE8803222L (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991013601A1 (en) *	1990-03-15	1991-09-19	Rhône-Poulenc Rorer International (Holdings) Inc.	Calcitonin suppository formulations
GB9013448D0 (en) *	1990-06-15	1990-08-08	Sandoz Ltd	Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
DE4222647A1 (de) *	1991-07-15	1993-01-21	Sandoz Ag	Peptid-zubereitungen
US5262172A (en) *	1992-06-19	1993-11-16	Digestive Care Inc.	Compositions of gastric acid-resistant microspheres containing buffered bile acids
JPH0776527A (ja) *	1993-06-28	1995-03-20	Hayashibara Biochem Lab Inc	半固形製剤とその製造方法
US7135191B2 (en) *	1997-09-04	2006-11-14	Zsolt Istvan Hertelendy	Urogenital or anorectal transmucosal vaccine delivery system
US7772220B2 (en) *	2004-10-15	2010-08-10	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
DE69924740T2 (de)	1998-07-24	2005-09-01	Yoo, Seo Hong	Klare wässrige lösungen enthaltend gallensäuren
US20050158408A1 (en) *	1998-07-24	2005-07-21	Yoo Seo H.	Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) *	1998-07-24	2007-12-04	Seo Hong Yoo	Preparation of aqueous clear solution dosage forms with bile acids
CN100558407C (zh) *	2000-02-04	2009-11-11	柳署弘	制备含有胆汁酸的澄清水溶液剂型
US7145125B2 (en)	2003-06-23	2006-12-05	Advanced Optical Technologies, Llc	Integrating chamber cone light using LED sources
PL2316473T3 (pl)	2003-07-23	2014-05-30	Novartis Ag	Zastosowanie kalcytoniny w chorobie zwyrodnieniowej stawów
EP1789057B1 (en) *	2004-08-30	2010-02-24	Seo Hong Yoo	Neuroprotective effect of solubilized udca in focal ischemic model
AU2005295541B2 (en) *	2004-10-15	2011-02-17	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
CA2585471A1 (en) *	2004-11-01	2006-05-11	Seo Hong Yoo	Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US8143314B1 (en)	2007-09-13	2012-03-27	Robert Carl Stover	Methods and formulations for treating ineffective or decreased esophageal motility
KR102287352B1 (ko) *	2015-06-30	2021-08-06	(주)아모레퍼시픽	화장료 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH211204A (de) *	1938-12-13	1940-08-31	Chem Ind Basel	Verfahren zur Herstellung einer Suppositoriengrundmasse.
US4164573A (en) *	1975-06-13	1979-08-14	Galinsky Alvin M	Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
JPS53107408A (en) *	1977-02-28	1978-09-19	Yamanouchi Pharmaceut Co Ltd	Micellar preparation for rectal infusion
ATE8584T1 (de) *	1980-01-16	1984-08-15	Hans Georg Prof. Dr. Weder	Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel.
JPS56118013A (en) *	1980-02-25	1981-09-16	Teijin Ltd	Calcitonin pharmaceutical and its preparation
JPS56138110A (en) *	1980-03-28	1981-10-28	Teijin Ltd	Suppository containing citric acid or salt thereof
JPS56138115A (en) *	1980-03-31	1981-10-28	Teijin Ltd	Suppository containing acidic amino acid or derivative thereof
DE3171774D1 (en) *	1980-03-31	1985-09-19	Teijin Ltd	Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
IL64397A0 (en) *	1981-01-07	1982-02-28	Weder Hans G	Process for the preparation of liposomal medicaments
IL70489A0 (en) *	1982-12-29	1984-03-30	Armour Pharma	Pharmaceutical compositions containing calcitonin
US4801577A (en) *	1987-02-05	1989-01-31	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
IT1222734B (it) *	1987-09-25	1990-09-12	Scalvo S P A	Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina

1988
- 1988-09-01 HU HU884522A patent/HU203204B/hu not_active IP Right Cessation
- 1988-09-06 DE DE3830245A patent/DE3830245A1/de not_active Withdrawn
- 1988-09-08 BE BE8801035A patent/BE1001937A3/fr not_active IP Right Cessation
- 1988-09-08 FR FR888811852A patent/FR2620331B1/fr not_active Expired - Lifetime
- 1988-09-12 PH PH37535A patent/PH24766A/en unknown
- 1988-09-12 LU LU87334A patent/LU87334A1/fr unknown
- 1988-09-12 CH CH3399/88A patent/CH677320A5/de not_active IP Right Cessation
- 1988-09-13 CA CA000577213A patent/CA1330417C/en not_active Expired - Fee Related
- 1988-09-13 NO NO884053A patent/NO175518C/no unknown
- 1988-09-13 SE SE8803222A patent/SE8803222L/xx not_active Application Discontinuation
- 1988-09-13 DK DK509888A patent/DK509888A/da not_active Application Discontinuation
- 1988-09-13 MY MYPI88001024A patent/MY103611A/en unknown
- 1988-09-13 PT PT88491A patent/PT88491B/pt not_active IP Right Cessation
- 1988-09-13 GB GB8821429A patent/GB2209670B/en not_active Expired - Lifetime
- 1988-09-13 AU AU22175/88A patent/AU614769B2/en not_active Ceased
- 1988-09-13 FI FI884191A patent/FI87889C/fi not_active IP Right Cessation
- 1988-09-13 NZ NZ226162A patent/NZ226162A/en unknown
- 1988-09-14 AT AT0224788A patent/AT396424B/de not_active IP Right Cessation
- 1988-09-14 JP JP63231394A patent/JPH01228919A/ja active Pending
- 1988-09-14 KR KR1019880011875A patent/KR970003052B1/ko not_active Expired - Lifetime
- 1988-09-14 IL IL87747A patent/IL87747A/xx not_active IP Right Cessation
- 1988-09-15 ES ES8802832A patent/ES2012119A6/es not_active Expired - Lifetime
- 1988-09-15 NL NL8802274A patent/NL8802274A/nl not_active Application Discontinuation
1991
- 1991-11-14 US US07/791,841 patent/US5149537A/en not_active Expired - Fee Related
1994
- 1994-03-10 HK HK193/94A patent/HK19394A/xx unknown
- 1994-07-15 CY CY176394A patent/CY1763A/en unknown

Also Published As

Publication number	Publication date
HK19394A (en)	1994-03-18
FI884191L (fi)	1989-03-16
FR2620331B1 (fr)	1991-11-08
GB2209670B (en)	1991-05-08
NO884053D0 (no)	1988-09-13
AT396424B (de)	1993-09-27
JPH01228919A (ja)	1989-09-12
NO175518C (no)	1994-10-26
FI87889C (fi)	1993-03-10
GB2209670A (en)	1989-05-24
DK509888D0 (da)	1988-09-13
SE8803222D0 (sv)	1988-09-13
SE8803222L (sv)	1989-03-16
PT88491A (pt)	1988-10-01
HUT47864A (en)	1989-04-28
KR890004680A (ko)	1989-05-09
AU614769B2 (en)	1991-09-12
CH677320A5 (no)	1991-05-15
DK509888A (da)	1989-03-16
LU87334A1 (fr)	1989-07-07
HU203204B (en)	1991-06-28
NO175518B (no)	1994-07-18
CY1763A (en)	1994-07-15
PT88491B (pt)	1992-11-30
KR970003052B1 (ko)	1997-03-14
NZ226162A (en)	1991-03-26
ATA224788A (de)	1993-01-15
MY103611A (en)	1993-08-28
GB8821429D0 (en)	1988-10-12
FI884191A0 (fi)	1988-09-13
BE1001937A3 (fr)	1990-04-17
ES2012119A6 (es)	1990-03-01
US5149537A (en)	1992-09-22
AU2217588A (en)	1989-04-20
CA1330417C (en)	1994-06-28
FI87889B (fi)	1992-11-30
PH24766A (en)	1990-10-01
DE3830245A1 (de)	1989-03-30
FR2620331A1 (fr)	1989-03-17
IL87747A0 (en)	1989-02-28
NO884053L (no)	1989-03-16
IL87747A (en)	1992-05-25

Publication	Publication Date	Title
NL8802274A (nl)	1989-04-03	Zetpillen.
DE69319440T2 (de)	1998-11-19	Herstellung von pharmazeutischen zusammensetzungen, die calcitonin enthalten
JP5557999B2 (ja)	2014-07-23	一体型医薬投薬形態
EP0097523B1 (en)	1988-01-13	Extended action controlled release compositions
EP0404490B1 (en)	1993-07-14	Fast dissolving dosage forms
DE69902893T2 (de)	2003-04-30	Schnellauflösende efavirenz-kapseln oder tabletten durch verwendung von super-zersetzern
DE69006094T2 (de)	1994-05-05	Pharmazeutische Zusammensetzungen.
BE1003093A3 (fr)	1991-11-19	Procede de preparation d'une composition pharmaceutique sous forme de microparticules.
DE3887494T2 (de)	1994-05-19	Ein Calcitonin sowie ein Glycyrrhizinat als Absorptionsförderer enthaltende Arzneimittel.
HUT49280A (en)	1989-09-28	Ointment for the peroral administration of medicine and process for producing the composition
SK12482001A3 (sk)	2002-01-07	Prášok na použitie v inhalátore na suché prášky, nosič na tento prášok a spôsob výroby prášku
EP0275468B1 (de)	1991-02-06	Clodronat-haltige Arzneimittel und Verfahren zur Herstellung derselben
US5393738A (en)	1995-02-28	Pharmaceutical compositions containing octreotide and excipients for oral or rectal administration
JP2002501015A (ja)	2002-01-15	リーシュマニア症の治療における経口投与のためのミルテフォシンを含有する固形医薬品
CA1203480A (en)	1986-04-22	Compressed products with retarded release of active substance
US20020107183A1 (en)	2002-08-08	Pharmaceutical preparations comprising cyclosporin for oral administration
DE3602577A1 (de)	1986-08-28	9,10-dihydrogenierte ergotalkaloide enthaltende pharmazeutische zusammensetzungen
CH669909A5 (no)	1989-04-28
EP0468182A1 (en)	1992-01-29	Pharmaceutical composition in powder form for nasal administration containing essentially calcitonin and a water-soluble excipient
RU2106142C1 (ru)	1998-03-10	Способ получения сердечно-сосудистого лекарственного препарата
CN116570619A (zh)	2023-08-11	铋剂在促进口服药物生物利用度中的应用
JPH10231250A (ja)	1998-09-02	抗骨粗鬆症剤
DD209112A5 (de)	1984-04-25	Umhuellungen zur oralen verabreichung pharmazeutischer praeparate
JPH1087482A (ja)	1998-04-07	解熱鎮痛剤
MXPA00005298A (en)	2001-07-03	Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Legal Events

Date	Code	Title
1990-03-01	A1B	A search report has been drawn up
1991-04-02	BV	The patent application has lapsed
1996-06-03	BV	The patent application has lapsed